Patients who have diabetes mellitus (both type 1 and type 2) have increased susceptibility to sepsis. Among the hormones that are altered by sepsis, there is an increase in the glucoregulatory peptide glucagon-like peptide-1 (GLP-1), and in animal models there is a specific increase in pancreatic-produced GLP-1 vs. glucagon. While the function of GLP-1 during sepsis is unknown, GLP-1 agonists have recently been of interest as an anti-inflammatory agent. We hypothesized that GLP-1 increases are necessary for dampening pancreatic inflammatory responses to sepsis in lean and HFD-fed mice. To model sepsis, we administered 100ng/g lipopolysaccharide (LPS) to C57BL/6 mice who had been fed HFD or chow for 12 weeks. We found that compared to vehicle treatment, LPS significantly increased plasma levels of GLP-1 in both HFD and chow-fed mice, but plasma GLP-1 was significantly higher and plasma glucose was significantly lower in HFD compared to chow-fed mice. To determine whether GLP-1 specifically regulated pancreatic inflammation, 24 hours after LPS we used flow cytometry to isolate pancreatic immune cells from chow-fed mice devoid of GLP-1 (GcgΔNull) and wild type (WT) mice. In chow-fed mice, we found approximately 20% more CD45+ cells in WT LPS treated mice compared to vehicle, and a similar percentage of CD45+ cells in LPS treated GcgΔNull mice compared to WT. In contrast, LPS administration to HFD-fed GcgΔNull mice, resulted in increased F4/80 positive cells compared to WT mice. Taken together, these data suggest that Gcg peptides are necessary to blunt LPS-induced inflammation in the pancreas and that GLP-1 physiologically regulates tissue inflammation. Future studies will determine whether the increased GLP-1 in HFD-fed mice is due to an increased inflammatory state or a decreased effectiveness of GLP-1.


E.M. Davis: None. C. Hutch: None. K. Kim: None. B. Maerz: None. M. Lehrke: Research Support; Self; Boehringer Ingelheim International GmbH, Merck Sharp & Dohme Corp., Novo Nordisk A/S. Other Relationship; Self; Amgen, AstraZeneca, Boehringer Ingelheim International GmbH, Lilly Diabetes, Novo Nordisk A/S. D.A. Sandoval: Research Support; Self; MedImmune, Novo Nordisk A/S.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at